First Turn Management LLC Cuts Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC

First Turn Management LLC lowered its stake in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 6.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,010,307 shares of the company’s stock after selling 149,167 shares during the quarter. Oric Pharmaceuticals accounts for about 1.9% of First Turn Management LLC’s portfolio, making the stock its 25th largest position. First Turn Management LLC’s holdings in Oric Pharmaceuticals were worth $16,444,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Oric Pharmaceuticals by 48.8% during the third quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company’s stock worth $55,802,000 after acquiring an additional 1,525,445 shares during the period. State Street Corp increased its position in shares of Oric Pharmaceuticals by 77.1% during the fourth quarter. State Street Corp now owns 4,258,397 shares of the company’s stock worth $34,834,000 after acquiring an additional 1,854,458 shares during the period. Orbimed Advisors LLC increased its position in shares of Oric Pharmaceuticals by 305.0% during the third quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company’s stock worth $43,701,000 after acquiring an additional 2,742,475 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Oric Pharmaceuticals by 114.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,939,285 shares of the company’s stock worth $15,863,000 after acquiring an additional 1,034,473 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Oric Pharmaceuticals by 7.4% during the fourth quarter. Geode Capital Management LLC now owns 1,750,694 shares of the company’s stock worth $14,323,000 after acquiring an additional 119,950 shares during the period. Hedge funds and other institutional investors own 95.05% of the company’s stock.

Oric Pharmaceuticals Price Performance

NASDAQ ORIC opened at $8.27 on Friday. Oric Pharmaceuticals, Inc. has a 1 year low of $7.23 and a 1 year high of $14.93. The company has a market capitalization of $856.11 million, a PE ratio of -5.74 and a beta of 1.04. The company has a fifty day moving average of $9.03 and a two-hundred day moving average of $10.17.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.03). On average, research analysts expect that Oric Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Stifel Nicolaus assumed coverage on Oric Pharmaceuticals in a report on Friday. They issued a “buy” rating and a $14.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Oric Pharmaceuticals in a report on Friday, May 22nd. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Oric Pharmaceuticals in a report on Monday, June 8th. Oppenheimer reissued an “outperform” rating and issued a $15.00 target price on shares of Oric Pharmaceuticals in a report on Tuesday, February 24th. Finally, Wall Street Zen lowered Oric Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. Fourteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.92.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.